HOME

I am the group leader of the Bioinformatics and Computational Biology (BCB) group within the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. The focus of my group is twofold: develop AI-driven innovative technology for small-molecule hit identification using data from DNA-encoded library screening, HTS, etc., and drug target analysis by rationalizing functional consequences of genetic variants on protein structure and function.

Prior to my current role, I was a postdoc at the Stanley Center for Psychiatric Disorder, Broad Institute, and at the Analytic and Translational Genetics Unit of Massachusetts General Hospital and Harvard Medical School. During her postdoctoral research in Mark Daly’s lab, she developed a statistical method for protein function-specific interpretation of genetic variants of 1,330 Mendelian disease genes. Following this work, she developed the Genomics to Proteins portal, a discovery tool for linking genetic screening outputs to protein sequence and structure for the full human proteome.

I earned my Ph.D. in Engineering and Applied Science, concentration: Computer Science and specialization: Bioinformatics and Machine Learning (2013-2017) from the University of New Orleans. I obtained my B.Sc. (2004-2009) and M.Sc. (2010-2013) in Computer Science and Engineering (CSE) from the Bangladesh University of Engineering & Technology (BUET). Prior to beginning the Ph.D., I worked as a lecturer for three years in the CSE department at my alma mater, BUET.  

During my Ph.D., I have been elected to membership in the Honor Society of Phi Kappa Phi, and have received Completer Award from the graduate council. Currently, I am a member of distinguished communities such as the American Society of Human Genetics (ASGH), Biophysical Society (BPS), and the International Society of Computational Biology (ISCB).

I am passionate about my research. To understand – and intervene on – the development of disease phenotype and therapeutically target the mechanism of actions, the Integrative and Translational Genetics in Medicine will require the inclusion of quantitative and analytical approaches to molecular and biophysical phenomena, and I am strongly motivated to continue my scientific exploration in this area through the application of data science and AI/machine learning.